



Call for Abstracts - 2024 SNO/ASCO CNS Metastases Conference



The SNO/ASCO CNS Metastases Conference — *Leveraging Multi-Sector Collaboration to Disrupt CNS Metastases* — will be held August 8-10, 2024, at the Sheraton Denver Downtown Hotel in Denver, Colorado.

The call for abstracts for the 2023 SNO/ASCO CNS Cancer Conference is now open. The submission deadline is on **Monday, April 8, 2024, at 11:59 PM ET.**

All accepted abstracts will be published as submitted in an online supplement to SNO's official journal, *Neuro-Oncology Advances*. To submit an abstract, [click here](#).

			<small>KOSELUGO is a registered trademark of the AstraZeneca group of companies. ALEXION and the Alexion logo are registered trademarks of Alexion Pharmaceuticals, Inc. © 2022, Alexion Pharmaceuticals, Inc. All rights reserved. US/KOS-NF1/0090 09/22</small> 
---	---	--	--

Call for Applications for the SNO Future Leaders Development Program

SNO FUTURE LEADERS DEVELOPMENT PROGRAM

The SNO Future Leaders Development Program seeks to cultivate the careers and train young physician-scientists to become future leaders in the field of neuro-oncology. This new program from SNO was developed to train young investigators to become leaders in brain tumor research, advance in their own academic departments and to lay the groundwork for leadership in the Society. Through mentorship and the application of a formalized training curriculum, this annual program will provide young investigators with practical skills and resources to allow them to excel in the field of neuro-oncology. [Apply Here!](#)



Neuro-Oncology Careers at Dartmouth Health
We have two openings for Neuro-Oncologists and are offering competitive salary and benefits with relocation assistance.

Dartmouth Health
dhproviders.org

From The Journals



From *Neuro-Oncology*

Lessons learned from phase 3 trials of immunotherapy for glioblastoma: Time for longitudinal sampling?

Glioblastoma (GBM)'s median overall survival is almost 21 months. Six phase 3 immunotherapy clinical trials have recently been published, yet 5/6 did not meet approval by regulatory bodies. For the sixth, approval is uncertain. Trial failures result from multiple factors, ranging from intrinsic tumor biology to clinical trial design. Understanding the clinical and basic science of these 6 trials is compelled by other immunotherapies reaching the point of advanced phase 3 clinical trial testing. We need to understand more of the science in human GBMs in early trials: the "window of opportunity" design may not be best to understand complex changes brought about by immunotherapeutic perturbations of the GBM microenvironment. The convergence of increased safety of image-guided biopsies with "multi-omics" of small cell numbers now permits longitudinal sampling of tumor and biofluids to dissect the complex temporal changes in the GBM microenvironment as a function of the immunotherapy. [Click here to read the full article.](#)



Conducting Phase 3 ACTION Study of
ONC201 (dordaviprone)
in H3 K27M-mutant Glioma | NCT05580562

[Learn More](#)

Upcoming Webinars




Barriers and Solutions to Equitable Access for Brain Tumor Survivors

Wednesday, December 13, 2023, 12:00 - 1:30 PM ET

For full details and complimentary registration, [click here.](#)

Adult Fellowship Match Educational Webinar

Applying for a Neuro-Oncology Fellowship: What You Need to Know
Thursday, December 14, 2023, 7:00 PM ET
For full details and to register, [click here](#).




Invax | NOW ENROLLING – Phase 2b study of IGV-001 in patients with newly diagnosed glioblastoma ([NCT04485949](#)) [LEARN MORE](#)

SNO Career Center



This Week's Featured Listing

The Yale Cancer Center and the Yale School of Medicine is seeking a Chief of Neuro-Oncology. This individual must be an outstanding academic clinician, trained in either medical oncology or neurology, and with a strong interest in translational research, the development of clinical trials, and novel diagnostic and treatment modalities. Emphasis is placed on the ability to lead clinical teams, conduct high impact clinical and scientific research, and mentor junior faculty and trainees. This position requires clinical care and clinical research activities as well as expectations for participating in the teaching and research missions of the institution. [Click here to apply or see other postings!](#)



The PROSPECT Study Is Enrolling at 43 Study Centers Across the US

For eligible patients with newly diagnosed or relapsed/refractory PCNSL

[Learn More About Enrolling Potentially Eligible Patients ▶](#)

PCNSL = Primary Central Nervous System Lymphoma.

ONO ONO PHARMA USA, INC.

COPYRIGHT © 2023 ONO PHARMA USA, INC. ALL RIGHTS RESERVED. 07/23

Upcoming SNO and SNO Affiliated Events



2024 SNO/ASCO CNS Metastases Conference

LEVERAGING MULTI-SECTOR COLLABORATION TO DISRUPT CNS METASTASES

August 8-10, 2024
Denver, Colorado

SNO Society for Neuro-Oncology

ASCO AMERICAN SOCIETY OF CLINICAL ONCOLOGY KNOWLEDGE CONQUERS CANCER



HOUSTON

29TH ANNUAL MEETING and EDUCATION DAY
OF THE SOCIETY FOR NEURO-ONCOLOGY

HOUSTON, TEXAS • NOVEMBER 21-24, 2024

2024 SNO/ASCO CNS Metastases Conference

[Abstract Submission Now Open!](#)

August 8-10, 2024
Denver, Colorado

29th Annual Meeting and Education Day

Save The Date!
November 21-24, 2024
Houston, Texas



21st International Symposium on Pediatric Neuro-Oncology

[Abstract Submission Now Open!](#)

June 28 - July 2, 2024
Philadelphia, PA

Advertise in the SNO Digest

Are you looking for an effective way to reach an audience of 18,000 neuro-oncology professionals? Advertising in the SNO Digest weekly newsletter is the perfect way to get the word out about your business! [Click here](#) for more information.

SNO Digest Co-Editors

- Iyad Alnahhas, MD, MSc
- Wenya Linda Bi, MD, PhD
- Nancy Wang, MD, MPH
- Holly Lindsay, MD, MS

SNO Team Admin Support

- Shelley Pressley - Director of Administration
- Gabrielle Griffin - Marketing and Communications Specialist

SNO Social Media Director

- Mustafa Khasraw, MD

Connect With SNO on Social Media

Are you following us on our socials? We're constantly sharing updates on SNO events and the latest news from the neuro-oncology field. Check us out on LinkedIn and Twitter.



SNO Digest is written and distributed by the Society for Neuro-Oncology. All content, including images, may not be reproduced unless permission is granted from SNO. If you would like to contribute to upcoming issues of the SNO Digest or if you have questions, please contact us at snodigest@soc-neuro-onc.org.

Society for Neuro-Oncology | [Website](#)
[Subscribe to the SNO Digest](#)



Society for Neuro-Oncology | PO 273296, Houston, TX 77277

Unsubscribe_megan@soc-neuro-onc.org

[Update Profile](#) | [Constant Contact Data Notice](#)

Sent by snodigest@soc-neuro-onc.org powered by



Try email marketing for free today!